ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.522,85
-0,42%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,09013
0,02%
Bitcoin
63.461,57
-2,14%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) News

VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DatumZeitQuelleÜberschriftSymbolFirma
28/04/202314h27Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VRDNViridian Therapeutics Inc
28/04/202314h25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VRDNViridian Therapeutics Inc
20/04/202319h41GlobeNewswire Inc.UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and OphthalmologyNASDAQ:VRDNViridian Therapeutics Inc
20/04/202314h00GlobeNewswire Inc.Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and OphthalmologyNASDAQ:VRDNViridian Therapeutics Inc
13/04/202301h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
12/04/202314h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VRDNViridian Therapeutics Inc
12/04/202314h00GlobeNewswire Inc.Viridian Therapeutics Appoints Tony Casciano as Chief Commercial OfficerNASDAQ:VRDNViridian Therapeutics Inc
04/04/202322h05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
13/03/202321h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
10/03/202323h08Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:VRDNViridian Therapeutics Inc
10/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
10/03/202321h22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VRDNViridian Therapeutics Inc
09/03/202313h25Edgar (US Regulatory)Annual Report (10-k)NASDAQ:VRDNViridian Therapeutics Inc
08/03/202313h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VRDNViridian Therapeutics Inc
08/03/202313h00GlobeNewswire Inc.Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatesNASDAQ:VRDNViridian Therapeutics Inc
07/03/202314h00GlobeNewswire Inc.Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology SocietyNASDAQ:VRDNViridian Therapeutics Inc
03/03/202322h05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
01/03/202314h00GlobeNewswire Inc.Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023NASDAQ:VRDNViridian Therapeutics Inc
28/02/202314h00GlobeNewswire Inc.Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care ConferenceNASDAQ:VRDNViridian Therapeutics Inc
14/02/202322h55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
14/02/202321h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
14/02/202320h24Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
14/02/202317h43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
14/02/202315h00Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
14/02/202312h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
10/02/202322h54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
10/02/202322h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
10/02/202322h50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
10/02/202322h48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
09/02/202318h02Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN

Kürzlich von Ihnen besucht

LSE
JGC
Jupiter Green Investment
LSE
100H
Am Ftse100 Usdh
NASDAQ
DOX
Amdocs
LSE
0ENJ
Hawesko
LSE
0R18
Best Buy
LSE
BC88
Chemring 7%prf
NASDAQ
MSFT
Microsoft
LSE
ORNT
Orient Telecoms
CSE
BDX
Common Shares
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten